Vivos Therapeutics (VVOS) Accounts Payables (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Accounts Payables for 8 consecutive years, with $2.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables rose 67.1% year-over-year to $2.9 million in Q2 2026; TTM through Jun 2026 was $2.9 million, a 67.1% increase from a year earlier, with the FY2025 full-year figure at $1.7 million, up 52.91% from the prior year.
• Accounts Payables was $2.9 million for Q2 2026 at Vivos Therapeutics, up from $2.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $2.9 million in Q2 2026 and troughed at $644000.0 in Q3 2022.
• A 5-year average of $1.6 million and a median of $1.5 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables jumped 137.27% in 2023 and slumped 51.74% in 2025, its largest moves.
• Over 5 years, Accounts Payables stood at $1.4 million in 2022, then jumped by 52.02% to $2.1 million in 2023, then plunged by 48.81% to $1.1 million in 2024, then jumped by 52.91% to $1.7 million in 2025, then soared by 75.46% to $2.9 million in 2026.
• The last three Accounts Payables figures came in at $2.9 million (Q2 2026), $2.0 million (Q1 2026), and $1.7 million (Q4 2025), per Business Quant data.